share_log

HC Wainwright & Co. Initiates Coverage On Inhibikase Therapeutics With Buy Rating, Announces Price Target of $5

Benzinga ·  Apr 18, 2023 06:18

HC Wainwright & Co. analyst Edward White initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment